Last reviewed 2026-05-28 · How we verify

Buprenorphine +CHC

Friends Research Institute, Inc. · Phase 3 active Small molecule Under review

Buprenorphine +CHC is a Partial mu-opioid receptor agonist with behavioral intervention Small molecule drug developed by Friends Research Institute, Inc.. It is currently in Phase 3 development for Opioid use disorder. Also known as: Suboxone.

Buprenorphine is a partial mu-opioid receptor agonist combined with a contingency management component (CHC) to treat opioid use disorder through both pharmacological and behavioral intervention.

Buprenorphine +CHC is a treatment for heroin addiction, as indicated by ClinicalTrials.gov. Buprenorphine is a small molecule that acts as a mu opioid receptor agonist, according to ChEMBL.

Likelihood of approval

55.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Buprenorphine +CHC
Also known as	Suboxone
Sponsor	Friends Research Institute, Inc.
Drug class	Partial mu-opioid receptor agonist with behavioral intervention
Target	Mu-opioid receptor (OPRM1)
Modality	Small molecule
Therapeutic area	Psychiatry / Addiction Medicine
Phase	Phase 3

Mechanism of action

Buprenorphine binds with high affinity to mu-opioid receptors, producing a ceiling effect on respiratory depression that makes it safer than full opioid agonists. The CHC (contingency-based counseling or contingency management component) reinforces abstinence and treatment adherence through behavioral incentives, enhancing the pharmacological efficacy of buprenorphine in opioid use disorder treatment.

Approved indications

Opioid use disorder

Common side effects

Headache
Constipation
Nausea
Insomnia
Withdrawal symptoms

Key clinical trials

Buprenorphine for Prisoners (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Buprenorphine +CHC CI brief — competitive landscape report
Buprenorphine +CHC updates RSS · CI watch RSS
Friends Research Institute, Inc. portfolio CI

Frequently asked questions about Buprenorphine +CHC

What is Buprenorphine +CHC?

Buprenorphine +CHC is a Partial mu-opioid receptor agonist with behavioral intervention drug developed by Friends Research Institute, Inc., indicated for Opioid use disorder.

How does Buprenorphine +CHC work?

Buprenorphine is a partial mu-opioid receptor agonist combined with a contingency management component (CHC) to treat opioid use disorder through both pharmacological and behavioral intervention.

What is Buprenorphine +CHC used for?

Buprenorphine +CHC is indicated for Opioid use disorder.

Who makes Buprenorphine +CHC?

Buprenorphine +CHC is developed by Friends Research Institute, Inc. (see full Friends Research Institute, Inc. pipeline at /company/friends-research-institute-inc).

Is Buprenorphine +CHC also known as anything else?

Buprenorphine +CHC is also known as Suboxone.

What drug class is Buprenorphine +CHC in?

Buprenorphine +CHC belongs to the Partial mu-opioid receptor agonist with behavioral intervention class. See all Partial mu-opioid receptor agonist with behavioral intervention drugs at /class/partial-mu-opioid-receptor-agonist-with-behavioral-intervention.

What development phase is Buprenorphine +CHC in?

Buprenorphine +CHC is in Phase 3.

What are the side effects of Buprenorphine +CHC?

Common side effects of Buprenorphine +CHC include Headache, Constipation, Nausea, Insomnia, Withdrawal symptoms.

What does Buprenorphine +CHC target?

Buprenorphine +CHC targets Mu-opioid receptor (OPRM1) and is a Partial mu-opioid receptor agonist with behavioral intervention.

Drug class: All Partial mu-opioid receptor agonist with behavioral intervention drugs
Target: All drugs targeting Mu-opioid receptor (OPRM1)
Manufacturer: Friends Research Institute, Inc. — full pipeline
Therapeutic area: All drugs in Psychiatry / Addiction Medicine
Indication: Drugs for Opioid use disorder
Also known as: Suboxone

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing